Skip to content

Acquisitions

Wilson Therapeutics Transaction

Effective April 11, 2018, Alexion has made a recommended public cash offer to the shareholders in Wilson Therapeutics to acquire all outstanding shares in Wilson Therapeutics by way of a tender offer. For transaction details and disclosures, please follow the link here.

 

Enobia Transaction

Effective February 7, 2012, Alexion completed its acquisition of Enobia Pharmaceuticals. The shareholders of Enobia Pharmaceuticals have appointed Shareholder Representative Services as the shareholders' respresentative. If you have questions relating to your rights as a former Enobia shareholder, please contact enobia@shareholderrep.com or 415-263-9018.

 

Taligen Transaction

Effective January 28, 2011, Alexion completed its acquisition of Taligen Therapeutics. The shareholders of Taligen Therapeutics have appointed Shareholder Representative Services as the shareholders' respresentative. If you have questions relating to your rights as a former Taligen shareholder, please contact taligen@shareholderrep.com or 415-263-9018.